All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How does treatment with ide-cel impact quality of life in RRMM?
Featured
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Michel Delforge, UZ Leuven, Leuven, BE. We asked, How does treatment with idecabtagene vicleucel impact quality of life (QoL) in relapsed/refractory multiple myeloma?
How does treatment with ide-cel impact quality of life in RRMM?
Delforge discusses the QoL data from the KarMMa-3 (NCT03651128) trial of idecabtagene vicleucel vs standard of care in relapsed/refractory multiple myeloma; he summarizes the overall efficacy data and provides an overview of the QoL outcomes. Delforge concludes by discussing outcomes in terms of global health status, functioning scores, symptom burden, and time taken to achieve an improvement in QoL.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox